---
title: "Genmab Discloses Orbis as New 5% Major Shareholder"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281419643.md"
description: "Genmab A/S announced that Orbis Investment Management Limited has become a major shareholder, holding 5.01% of the company's shares as of March 31, 2026. This disclosure highlights increasing institutional interest in Genmab, potentially boosting investor confidence in its antibody-focused pipeline. While the filing does not change daily operations, it may influence future governance and market perception. The latest analyst rating for GMAB stock is a Hold with a price target of $28.00, reflecting strong financial performance but concerns over leverage and earnings quality."
datetime: "2026-04-01T20:02:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281419643.md)
  - [en](https://longbridge.com/en/news/281419643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281419643.md)
---

# Genmab Discloses Orbis as New 5% Major Shareholder

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An announcement from Genmab ( (GMAB) ) is now available.

Genmab A/S reported on April 1, 2026, that Orbis Investment Management Limited had become a major shareholder as of March 31, 2026, holding 3,221,620 shares, equivalent to 5.01% of Genmab’s share capital and voting rights. The disclosure, made under Denmark’s capital markets rules, underscores growing institutional interest in the biotech group and may signal increased investor confidence in Genmab’s antibody-focused pipeline and long-term growth prospects.

The major shareholder notification formalizes Orbis’s stake, giving the fund a meaningful voice in shareholder decisions at a time when Genmab continues to advance late-stage clinical programs. While the filing itself does not alter day-to-day operations, the enlarged institutional backing could influence future governance dynamics and market perception of the company’s strategic direction.

The most recent analyst rating on (GMAB) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.

**Spark’s Take on GMAB Stock**

According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.

The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.

To see Spark’s full report on GMAB stock, click here.

**More about Genmab**

Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines to treat cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a broad portfolio of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates and immune-modulating antibodies, powering eight approved medicines and a late-stage clinical pipeline.

**Average Trading Volume:** 1,763,501

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $16.34B

Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)

## Related News & Research

- [Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY](https://longbridge.com/en/news/285581260.md)
- [Genmab Discloses CFO Insider Share Sale Under EU Market Abuse Rules](https://longbridge.com/en/news/276478570.md)
- [Harris Teeter Offers GLP-1 Medications, Nutrition Support and Cost-Saving Options | KR Stock News](https://longbridge.com/en/news/284888289.md)
- [CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine](https://longbridge.com/en/news/285586166.md)
- [08:11 ETNew toolkit for obesity care helps clinicians integrate lifestyle interventions with obesity medications](https://longbridge.com/en/news/285203714.md)